The board (the "Board") of directors of CARsgen Therapeutics Holdings Limited announced that Dr. Hua JIANG ("Dr. Jiang") has been appointed as executive Director of the Company with effect from August 1, 2022 (Appointment Date). The biographical details of Dr. Jiang are set out below: Dr. Jiang has about 18 years of work experience in the field of cancer biotherapy. She currently serves as Vice President of Early Discovery of CARsgen, and is responsible for formulating the strategy of early discovery and the construction of R&D pipeline.

Dr. Jiang joined the Company in April 2021 as Senior Director of Immune Cell Research and Development Department, and is responsible for the research work of Immune Cell Research and Development and Preclinical Pharmacology. Dr. Jiang has achieved outstanding outcomes, not only by strengthening the technology platform but also by expanding a number of candidate product pipelines. Prior to joining the Company, from July 2007 to April 2021, Dr. Jiang was responsible for the research and development of antibody and CAR T-cells, as well as the related mechanism in Shanghai Cancer Institute.

Dr. Jiang was a professor in Shanghai Cancer Institute and a doctoral supervisor at Shanghai Jiao Tong University School of Medicine. Dr. Jiang has published more than 20 SCI papers, including JNCI, CCR, Molecular Therapy and other professional journals. She published the world's first paper about CLDN18.2 and EGFR/EGFRvIII CAR T Therapy as the first author and the world ' s first paper of small molecule inhibitor and CAR T combination therapy in solid tumors as the co-corresponding author.

Dr. Jiang earned her Bachelor's degree in Clinical Medicine from Jining Medical College in 2001. She obtained her Master's degree in Pathogen Biology from Shandong University in 2004 and Ph.D. in Pathogen Biology from Fudan University in 2007.